CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients with Acute Lymphoblastic Leukemia: Guidelines

Last updated: March 5, 2018
Project Number: RB1200-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What are the evidence-based guidelines regarding best practices for patient care for pediatric patients with acute lymphoblastic leukemia undergoing chimeric antigen receptor t-cell therapy?
  2. What are the evidence-based guidelines regarding best practices for the transfer of pediatric patients with acute lymphoblastic leukemia undergoing chimeric antigen receptor t-cell therapy to the pediatric intensive care unit?

Key Message

No literature was identified regarding chimeric antigen receptor T-Cell therapy for pediatric patients with acute lymphoblastic leukemia.